rss
Br J Ophthalmol 2008;92:74-75 doi:10.1136/bjo.2007.128942
  • Original Article
    • Clinical science

Combined Pegaptanib sodium (Macugen) and photodynamic therapy in predominantly classic juxtafoveal choroidal neovascularisation in age related macular degeneration

  1. C Calvo-González1,
  2. J Reche-Frutos1,
  3. J Donate-López1,
  4. J García-Feijoó1,
  5. M Leila2,
  6. C Fernández-Pérez1,
  7. J Garcia-Sánchez1
  1. 1
    Hospital Universitario Clínico San Carlos, Madrid, Spain
  2. 2
    Magrabi Eye Hospital, Egypt
  1. Cristina Calvo-González, C/Profesor Martín Lagos s/n 28040, Madrid, Spain; calvo_glez{at}yahoo.es
  • Accepted 11 September 2007

Abstract

Aims: This prospective, open label, non-comparative, observational case series evaluates 6-month results of Pegaptanib Sodium (Macugen®) and Photodynamic Therapy (PDT) in predominantly classic juxtafoveal choroidal neovascularisation (CNV) in age-related macular degeneration (AMD) in seven eyes of seven patients.

Results: Best corrected visual acuity (BCVA) diminished with a mean of five letters. Initial area of CNV increased significantly from 1.4 mm2 to 2.7 mm2. There was a significant increase in the greatest linear dimension (GLD) from 1280.3 μm to 2065.7 μm at the 24-week follow-up.

Conclusion: Predominantly classic juxtafoveal CNVs are highly aggressive lesions that demonstrate poor response despite combined therapy using PDT and Macugen.

Footnotes

  • Competing interests: None.

This Article

  1. Abstract
  2. Full text
  3. PDF

Responses

  1. Submit a response
  2. No responses published

Register for free content

The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.